Patents by Inventor Annabelle Rodriguez Oquendo

Annabelle Rodriguez Oquendo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10751388
    Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG-3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: August 25, 2020
    Inventor: Annabelle Rodriguez Oquendo
  • Publication number: 20190365855
    Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG-3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
    Type: Application
    Filed: March 21, 2019
    Publication date: December 5, 2019
    Inventor: Annabelle Rodriguez Oquendo
  • Patent number: 10265379
    Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: April 23, 2019
    Inventor: Annabelle Rodriguez Oquendo
  • Patent number: 9995759
    Abstract: A method for determining whether a subject has or is predisposed to abnormal expression of inflammasomes and/or to dysfunctional HDL suitable for use in diagnosing atherosclerosis, chronic inflammatory disease, Incident Cardiovascular Disease (ICD) and other pathologies characterized by an inflammatory response. Specifically, a protein assay that measures LAG-3 can be used as a diagnostic predictor of pathologies such as infection, inflammation, chronic inflammatory disease, and coronary artery disease. The diagnostic is combined with the therapeutic use of a remediating drug for treatment.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: June 12, 2018
    Inventor: Annabelle Rodriguez Oquendo
  • Publication number: 20170312338
    Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
    Type: Application
    Filed: September 12, 2016
    Publication date: November 2, 2017
    Inventor: Annabelle Rodriguez Oquendo
  • Publication number: 20160324802
    Abstract: A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 10, 2016
    Inventor: Annabelle Rodriguez Oquendo
  • Patent number: 9334538
    Abstract: A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: May 10, 2016
    Inventor: Annabelle Rodriguez Oquendo
  • Publication number: 20150355203
    Abstract: A method for determining whether a subject has or is predisposed to abnormal expression of inflammasomes and/or to dysfunctional HDL suitable for use in diagnosing atherosclerosis, chronic inflammatory disease, Incident Cardiovascular Disease (ICD) and other pathologies characterized by an inflammatory response. Specifically, a protein assay that measures LAG-3 can be used as a diagnostic predictor of pathologies such as infection, inflammation, chronic inflammatory disease, and coronary artery disease. The diagnostic is combined with the therapeutic use of a remediating drug for treatment.
    Type: Application
    Filed: April 17, 2015
    Publication date: December 10, 2015
    Inventor: Annabelle Rodriguez Oquendo
  • Publication number: 20130345187
    Abstract: A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.
    Type: Application
    Filed: December 6, 2012
    Publication date: December 26, 2013
    Inventor: Annabelle Rodriguez Oquendo